DNA/MVA vaccines for HIV/AIDS

Smita Iyer, Rama R. Amara

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous "prime-boost" vaccination regimens. Direct injection of plasmid DNA into the muscle induces T- and B-cell responses against foreign antigens. However, the insufficient magnitude of this response has led to the development of approaches for enhancing the immunogenicity of DNA vaccines. The last two decades have seen significant progress in the DNA-based vaccine platform with optimized plasmid constructs, improved delivery methods, such as electroporation, the use of molecular adjuvants and novel strategies combining DNA with viral vectors and subunit proteins. These innovations are paving the way for the clinical application of DNA-based HIV vaccines. Here, we review preclinical studies on the DNA-prime/modified vaccinia Ankara(MVA)-boost vaccine modality for HIV. There is a great deal of interest in enhancing the immunogenicity of DNA by engineering DNA vaccines to co-express immune modulatory adjuvants. Some of these adjuvants have demonstrated encouraging results in preclinical and clinical studies, and these data will be examined, as well.

Original languageEnglish (US)
Pages (from-to)160-178
Number of pages19
JournalVaccines
Volume2
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Vaccinia
AIDS Vaccines
DNA Vaccines
DNA
Plasmids
Antigens
Electroporation
Viral Proteins
Vaccination
B-Lymphocytes
HIV
Muscles
Injections

Keywords

  • Adjuvant
  • CD40L
  • GM-CSF
  • Rhesus macaque
  • SIV

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Iyer, S., & Amara, R. R. (2014). DNA/MVA vaccines for HIV/AIDS. Vaccines, 2(1), 160-178. https://doi.org/10.3390/vaccines2010160

DNA/MVA vaccines for HIV/AIDS. / Iyer, Smita; Amara, Rama R.

In: Vaccines, Vol. 2, No. 1, 01.01.2014, p. 160-178.

Research output: Contribution to journalReview article

Iyer, S & Amara, RR 2014, 'DNA/MVA vaccines for HIV/AIDS', Vaccines, vol. 2, no. 1, pp. 160-178. https://doi.org/10.3390/vaccines2010160
Iyer, Smita ; Amara, Rama R. / DNA/MVA vaccines for HIV/AIDS. In: Vaccines. 2014 ; Vol. 2, No. 1. pp. 160-178.
@article{f7c3838c2aea4393936c3572b7415458,
title = "DNA/MVA vaccines for HIV/AIDS",
abstract = "Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous {"}prime-boost{"} vaccination regimens. Direct injection of plasmid DNA into the muscle induces T- and B-cell responses against foreign antigens. However, the insufficient magnitude of this response has led to the development of approaches for enhancing the immunogenicity of DNA vaccines. The last two decades have seen significant progress in the DNA-based vaccine platform with optimized plasmid constructs, improved delivery methods, such as electroporation, the use of molecular adjuvants and novel strategies combining DNA with viral vectors and subunit proteins. These innovations are paving the way for the clinical application of DNA-based HIV vaccines. Here, we review preclinical studies on the DNA-prime/modified vaccinia Ankara(MVA)-boost vaccine modality for HIV. There is a great deal of interest in enhancing the immunogenicity of DNA by engineering DNA vaccines to co-express immune modulatory adjuvants. Some of these adjuvants have demonstrated encouraging results in preclinical and clinical studies, and these data will be examined, as well.",
keywords = "Adjuvant, CD40L, GM-CSF, Rhesus macaque, SIV",
author = "Smita Iyer and Amara, {Rama R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.3390/vaccines2010160",
language = "English (US)",
volume = "2",
pages = "160--178",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "1",

}

TY - JOUR

T1 - DNA/MVA vaccines for HIV/AIDS

AU - Iyer, Smita

AU - Amara, Rama R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous "prime-boost" vaccination regimens. Direct injection of plasmid DNA into the muscle induces T- and B-cell responses against foreign antigens. However, the insufficient magnitude of this response has led to the development of approaches for enhancing the immunogenicity of DNA vaccines. The last two decades have seen significant progress in the DNA-based vaccine platform with optimized plasmid constructs, improved delivery methods, such as electroporation, the use of molecular adjuvants and novel strategies combining DNA with viral vectors and subunit proteins. These innovations are paving the way for the clinical application of DNA-based HIV vaccines. Here, we review preclinical studies on the DNA-prime/modified vaccinia Ankara(MVA)-boost vaccine modality for HIV. There is a great deal of interest in enhancing the immunogenicity of DNA by engineering DNA vaccines to co-express immune modulatory adjuvants. Some of these adjuvants have demonstrated encouraging results in preclinical and clinical studies, and these data will be examined, as well.

AB - Since the initial proof-of-concept studies examining the ability of antigen-encoded plasmid DNA to serve as an immunogen, DNA vaccines have evolved as a clinically safe and effective platform for priming HIV-specific cellular and humoral responses in heterologous "prime-boost" vaccination regimens. Direct injection of plasmid DNA into the muscle induces T- and B-cell responses against foreign antigens. However, the insufficient magnitude of this response has led to the development of approaches for enhancing the immunogenicity of DNA vaccines. The last two decades have seen significant progress in the DNA-based vaccine platform with optimized plasmid constructs, improved delivery methods, such as electroporation, the use of molecular adjuvants and novel strategies combining DNA with viral vectors and subunit proteins. These innovations are paving the way for the clinical application of DNA-based HIV vaccines. Here, we review preclinical studies on the DNA-prime/modified vaccinia Ankara(MVA)-boost vaccine modality for HIV. There is a great deal of interest in enhancing the immunogenicity of DNA by engineering DNA vaccines to co-express immune modulatory adjuvants. Some of these adjuvants have demonstrated encouraging results in preclinical and clinical studies, and these data will be examined, as well.

KW - Adjuvant

KW - CD40L

KW - GM-CSF

KW - Rhesus macaque

KW - SIV

UR - http://www.scopus.com/inward/record.url?scp=85019427452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019427452&partnerID=8YFLogxK

U2 - 10.3390/vaccines2010160

DO - 10.3390/vaccines2010160

M3 - Review article

AN - SCOPUS:85019427452

VL - 2

SP - 160

EP - 178

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 1

ER -